Capital Fund Management S.A. Has $2.40 Million Stake in 10x Genomics $TXG

Key Points

• Capital Fund Management S.A. has reduced its stake in 10x Genomics by 10.0% in the first quarter, now owning 274,461 shares valued at approximately $2.4 million.
• 10x Genomics reported earnings of $0.28 per share for the last quarter, significantly surpassing analysts' estimates of a loss of $0.35 per share, with revenues up 12.9% year-over-year.
• Several institutional investors have increased their holdings in 10x Genomics, contributing to a total institutional ownership of 84.68%.

Capital Fund Management S.A. lessened its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 10.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 274,461 shares of the company's stock after selling 30,371 shares during the period. Capital Fund Management S.A. owned about 0.22% of 10x Genomics worth $2,396,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TXG. EntryPoint Capital LLC bought a new stake in 10x Genomics during the 1st quarter valued at $420,000. Fox Run Management L.L.C. bought a new stake in 10x Genomics during the 1st quarter valued at $270,000. Russell Investments Group Ltd. raised its stake in 10x Genomics by 385.6% during the 1st quarter. Russell Investments Group Ltd. now owns 81,669 shares of the company's stock valued at $713,000 after acquiring an additional 64,851 shares in the last quarter. Nuveen LLC acquired a new position in shares of 10x Genomics during the 1st quarter valued at $1,755,000. Finally, Invesco Ltd. increased its position in shares of 10x Genomics by 62.1% during the 1st quarter. Invesco Ltd. now owns 191,332 shares of the company's stock valued at $1,670,000 after purchasing an additional 73,265 shares during the period. Institutional investors own 84.68% of the company's stock.

Insider Transactions at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,149 shares of company stock worth $539,865. Company insiders own 9.39% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the company a "hold" rating in a research report on Friday, August 8th. The Goldman Sachs Group lowered their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Barclays restated an "overweight" rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Finally, Bank of America lifted their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $13.54.

10x Genomics Trading Down 1.8%

10x Genomics stock traded down $0.26 during trading hours on Friday, reaching $14.02. 892,655 shares of the company were exchanged, compared to its average volume of 3,376,397. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.76. The stock has a 50-day moving average of $12.85 and a 200 day moving average of $10.69. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -20.04 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics's revenue was up 12.9% compared to the same quarter last year. During the same period last year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.